Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Mar 29, 2024

c-Myc Antibody

RRID:AB_2151827 Type: Antibody

Proper Citation

(Cell Signaling Technology Cat# 9402, RRID:AB_2151827)

Antibody Information

URL: http://antibodyregistry.org/AB_2151827

Proper Citation: (Cell Signaling Technology Cat# 9402, RRID:AB_2151827)

Target Antigen: c-Myc

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: W, IP, ChIP. Consolidation on 10/2018: AB_10693752,

AB_2151827.

Antibody Name: c-Myc Antibody

Description: This polyclonal targets c-Myc

Target Organism: human, mouse, rat

Antibody ID: AB_2151827

Vendor: Cell Signaling Technology

Catalog Number: 9402

Ratings and Alerts

No rating or validation information has been found for c-Myc Antibody.

No alerts have been found for c-Myc Antibody.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 44 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Wang Y, et al. (2023) Dihydroartemisinin inhibited stem cell-like properties and enhanced oxaliplatin sensitivity of colorectal cancer via AKT/mTOR signaling. Drug development research.

Yao H, et al. (2023) A MYC-controlled redox switch protects B lymphoma cells from EGR1-dependent apoptosis. Cell reports, 42(8), 112961.

Antal CE, et al. (2023) A super-enhancer-regulated RNA-binding protein cascade drives pancreatic cancer. Nature communications, 14(1), 5195.

Barbagallo F, et al. (2022) Functional Interaction Between the Oncogenic Kinase NEK2 and Sam68 Promotes a Splicing Program Involved in Migration and Invasion in Triple-Negative Breast Cancer. Frontiers in oncology, 12, 880654.

Zhu Y, et al. (2022) The long noncoding RNA glycoLINC assembles a lower glycolytic metabolon to promote glycolysis. Molecular cell, 82(3), 542.

Boukouris AE, et al. (2022) A reversible metabolic stress-sensitive regulation of CRMP2A orchestrates EMT/stemness and increases metastatic potential in cancer. Cell reports, 38(11), 110511.

Gorityala S, et al. (2022) Downregulation of Dihydrotestosterone and Estradiol Levels by HEXIM1. Endocrinology, 163(1).

Morris V, et al. (2022) Hypoxic, glycolytic metabolism is a vulnerability of B-acute lymphoblastic leukemia-initiating cells. Cell reports, 39(4), 110752.

Xu C, et al. (2022) A NSD3-targeted PROTAC suppresses NSD3 and cMyc oncogenic nodes in cancer cells. Cell chemical biology, 29(3), 386.

, et al. (2022) Loss of VOPP1 Contributes to BET Inhibitor Acquired Resistance in Non-Small Cell Lung Cancer Cells. Molecular cancer research : MCR, 20(12), 1785.

Bernier M, et al. (2022) Deprogramming metabolism in pancreatic cancer with a bi-functional GPR55 inhibitor and biased ?2 adrenergic agonist. Scientific reports, 12(1), 3618.

Ebata T, et al. (2021) Flightless I is a catabolic factor of chondrocytes that promotes hypertrophy and cartilage degeneration in osteoarthritis. iScience, 24(6), 102643.

Sheppard HE, et al. (2021) Targeted brachyury degradation disrupts a highly specific autoregulatory program controlling chordoma cell identity. Cell reports. Medicine, 2(1), 100188.

Villa E, et al. (2021) mTORC1 stimulates cell growth through SAM synthesis and m6A mRNA-dependent control of protein synthesis. Molecular cell, 81(10), 2076.

Gonzalez FJ, et al. (2021) Constitutive androstane receptor induced-hepatomegaly and liver regeneration is partially via yes-associated protein activation. Acta pharmaceutica Sinica. B, 11(3), 727.

Hao L, et al. (2021) Repurposing the anthelmintic praziquantel to treat psoriasis. British journal of pharmacology, 178(23), 4726.

Tang HW, et al. (2021) mTORC1 promotes cell growth via m6A-dependent mRNA degradation. Molecular cell, 81(10), 2064.

Asara JM, et al. (2021) The mTORC1-mediated activation of ATF4 promotes protein and glutathione synthesis downstream of growth signals. eLife, 10.

Terracciano F, et al. (2021) MYC Upregulation Confers Resistance to Everolimus and Establishes Vulnerability to Cyclin-Dependent Kinase Inhibitors in Pancreatic Neuroendocrine Neoplasm Cells. Neuroendocrinology, 111(8), 739.

Garcia I, et al. (2021) Kel1 is a phosphorylation-regulated noise suppressor of the pheromone signaling pathway. Cell reports, 37(13), 110186.